Use

Quest’s BRAF Mutation Analysis for papillary thyroid cancer identifies mutations within the BRAF gene—most notably V600E—that are commonly observed in papillary thyroid carcinoma and are associated with poorer prognosis and disease recurrence. The test helps clinicians confirm malignancy and may inform risk stratification and management decisions in patients with suspected or confirmed papillary thyroid carcinoma. It may also aid in therapeutic planning if targeted therapies are considered.

Not provided.